RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > The REMS in Practice: Recent Trends

The REMS in Practice: Recent Trends

Posted 01 July 2010

In the drug approval process, the US Food and Drug Administration (FDA) must balance the demand for approval of new therapies with the need to ensure the safety of products that have only been tested in clinical trials studying a limited number-hundreds to thousands-of patients. The 2007 Food and Drug Administration Amendments Act (FDAAA)1 grants FDA the authority to require Risk Evaluation and Mitigation Strategies (REMS) to be implemented postapproval when deemed necessary for a favorable risk/benefit balance for a product.

 

© 2022 Regulatory Affairs Professionals Society.